• Can Restricting Fructose Intake Reduce Fatty Liver Disease in Children?

Can Restricting Fructose Intake Reduce Fatty Liver Disease in Children?

Reducing dietary fructose for as little as 9 days decreases liver fat, visceral fat, and de novo lipogenesis and increases insulin sensitivity, secretion, and clearance in children with obesity and metabolic syndrome, researchers report in the September issue of Gastroenterology. These findings support efforts to reduce sugar consumption. Consumption of sugar

Read more
  • What is the Best Management Strategy for Patients With NAFLD?

What is the Best Management Strategy for Patients With NAFLD?

Management of patients with non-alcoholic fatty liver disease (NAFLD) requires combined efforts of general practitioners, hepatologists, and other experts, Herbert Tilg explains in a Mentoring, Education, and Training Corner article in the August issue of Gastroenterology. NAFLD has become the most common liver disease worldwide. It ranges from simple steatosis in the absence

Read more
  • What are the Most Accurate Non-invasive Techniques for Measuring Liver Fibrosis and Steatosis?

What are the Most Accurate Non-invasive Techniques for Measuring Liver Fibrosis and Steatosis?

Magnetic resonance elastography (MRE) is more accurate than transient elastography (TE) in identifying liver fibrosis of stage 1 or more, researchers report in the February issue of Gastroenterology, using biopsy analysis as the standard. They also show that MRI-based proton density fat fraction (MRI-PDFF) analysis is more accurate than TE-based

Read more
  • Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Mice with defects in intestinal epithelial permeability develop more severe steatohepatitis when placed on a diet high in saturated fat, fructose, and cholesterol (HFCD) than control mice, and colon tissues from patients with non-alcoholic fatty liver disease (NAFLD) have similar defects in intestinal epithelial permeability, researchers report in the October

Read more
  • How Could Variants in TM6SF2 Affect Risk for NAFLD?

How Could Variants in TM6SF2 Affect Risk for NAFLD?

The human transmembrane 6 superfamily member 2 (TM6SF2) protein regulates cholesterol metabolism in mice, researchers report in the May issue of Gastroenterology. These findings provide insight into the how a variant of TM6SF2 (encoding the amino acid change E167K) reduces total cholesterol and low-density lipoprotein cholesterol (LDL-c) levels in humans, and

Read more

Advances in PSC, NAFLD, and Liver Transplantation for Patients with HCV Infection reported at International Liver Congress

A chemical cousin of an existing drug shows promise for patients with primary sclerosing cholangitis (PSC), a larger waistline increases risk for severe nonalcoholic fatty liver disease (NAFLD), and livers from hepatitis C virus (HCV)-infected donors are safe for transplant into HCV-infected recipients were all among the exciting findings reported

Read more
  • Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • What Causes Different Types of Fatty Liver Disease?

What Causes Different Types of Fatty Liver Disease?

Hepatic steatosis and steatohepatitis are increasing in prevalence, and can progress to histologically identical, more severe liver disease. They are associated with 3 main factors: alcohol, obesity or metabolic syndrome, and exposure to toxins. Researchers review the similarities, differences, and pathogenic mechanisms of alcohol-associated steatohepatitis (ASH), nonalcoholic steatohepatitis (NASH), and toxicant-associated fatty liver

Read more
  • Does Weight Loss Resolve Fatty Liver Disease?

Does Weight Loss Resolve Fatty Liver Disease?

Two separate studies in the August issue of Gastroenterology show that weight loss, via diet or bariatric surgery, reduce features of non-alcoholic steatohepatitis (NASH). Eduardo Vilar-Gomez et al associated extent of weight loss, produced by lifestyle changes, with level of improvement in histologic features of NASH. The highest rates of NASH reduction

Read more
  • A Quantitative Ultrasound Technology to Identify Patients with NAFLD and Quantify Steatohepatitis

A Quantitative Ultrasound Technology to Identify Patients with NAFLD and Quantify Steatohepatitis

A new quantitative ultrasound (QUS)  can accurately identify patients with non-alcoholic fatty liver disease (NAFLD) and quantify hepatic steatosis, researchers report in the July issue of Clinical Gastroenterology and Hepatology. With further validation, QUS could be an inexpensive, widely used technique to screen the general or at-risk population for NAFLD. The estimated prevalence of NAFLD

Read more